Tadalafil shows promise for relief of lower urinary tract symptoms associated with BPHAugust 19, 2008Men with signs of benign prostatic hyperplasia (BPH) can be helped with a daily dose of erectile dysfunction drug tadalafil (Cialis®) to relieve associated lower urinary tract symptoms (LUTS), according to a new study published in the October 2008 issue of The Journal of Urology. Researchers from the University of Texas Southwestern Medical Center at Dallas, Northwestern University and Lilly Research Laboratories report on a randomized, double-blind, placebo-controlled study of over 1000 men in ten countries. Claus G. Roehrborn, MD, Professor of Urology, University of Texas Southwestern Medical Center, states, "Since reports of erectile dysfunction (ED) incidence, pathophysiology and treatment have shown a possible link between BPH LUTS and ED. PDE5 inhibitors like tadalafil (Cialis®) have received increased attention for treating BPH LUTS, although they are currently only approved for ED. The half-life of tadalafil is 17.5 hours, making it suitable as once daily therapy. Although the precise mechanism of action by which PDE5 inhibitors may alleviate LUTS is not completely understood, several putative mechanisms are currently under investigation." Men with signs of BPH may experience LUTS, such as urinary frequency, urgency, intermittence, nocturia, straining, incomplete emptying or a weak urinary stream. LUTS increase with age with an overall prevalence of greater than 50% in men 50 years or older. Drugs currently used to treat these symptoms can produce unwanted side effects, including dizziness, low blood pressure and sexual dysfunction.
Participants in the tadalafil study were required to have at least a 6-month history of LUTS secondary to BPH. Subjects with a high PSA (more than 10 ng/ml) were excluded, as were subjects with other complicating conditions or conflicting drug treatments. Anyone who had undergone treatment for erectile dysfunction or other BPH treatments underwent a 4-week treatment-free screening period. All participants then received placebo for 4 weeks prior to randomization. The 1056 subjects were then divided randomly into 5 groups that received a placebo, or doses of 2.5, 5.0, 10.0 or 20.0 mg/day of tadalafil. Using the International Prostate Symptom Score (I-PSS), a validated seven-item questionnaire about LUTS occurring within the last month, the researchers found that all doses of tadalafil were superior to placebo for relieving LUTS, with statistically significant effects at 4, 8 and 12 weeks. The treatments decreased I-PSS scores from 3.9 to 5.2 points in the different dosage groups, a clinically meaningful improvement according to the guidelines of the American Urological Association. Of the doses studied, 5 mg per day improved the I-PSS by 4.9 points and provided the best risk-benefit profile. Elsevier Health Sciences | |||||||||||||||||||
|
Related Tadalafil Current Events and Tadalafil News Articles Erectile dysfunction related to sleep apnea may persist, but is treatable For sufferers of sleep apnea, erectile dysfunction (ED) is often part of the package. New research indicates that ED in cases of obstructive sleep apnea syndrome (OSAS) may be linked to the chronic intermittent hypoxia-oxygen deprivation- (CIH) that patients with OSAS experience during episodes of obstructed breathing. Mayo Clinic Proceedings: Men with chronic heart failure can have active sex lives Although medication can help extend the lives of men with chronic heart failure, several factors associated with this disease can interfere with a person's ability to engage in and enjoy sexual activities. Medication appears helpful for treatment of erectile dysfunction in men with spinal cord injuries The drug tadalafil appears to improve erectile function in men with spinal cord injuries, according to an article posted online today that will appear in the November 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals. Cialis improves sexual function for prostate cancer survivors In the first randomized trial of its kind, Tadalafil, a drug typically prescribed for erectile dysfunction in men, has been proven to increase the sexual function of prostate cancer survivors. Studies to date say erectile dysfunction drugs affect other systems, mostly for the better Since the Food and Drug Administration gave Viagra® (sildenafil) its approval in 1998, "erectile dysfunction" has become a household term — probably to the chagrin of many parents fielding questions from their kids watching TV. Lack of key enzyme associated with development of rare tumor Researchers at the National Institutes of Health have discovered that a rare tumor of the adrenal glands appears to result from a genetic deficiency of an important enzyme. The enzyme is one of a class of enzymes involved in halting a cell's response to hormones and appears to stop cells from dividing. Researchers Debate Recreational Use of PDE-5 Inhibitors Leaders in the field of sexual medicine will actively debate the use of oral pills for erectile dysfunction (ED) at the 7th Congress of the European Society for Sexual Medicine in London, UK. Bigger is better when it comes to the G spot DRUGS such as Viagra should work for some women- especially if they have a big G spot. This spot, famed for producing spectacular orgasms, turns out to be awash with the enzymes that these drugs act on. The term G spot, coined by Ernest Grafenberg in 1950, refers to an area a few centimetres up inside the vagina on the side closest to a woman`s stomach (see above). Buried in the flesh here are the Skene`s glands, the female equivalent of the prostate gland. In men, the prostate produces the watery component of semen. In women, Skene`s glands are also thought to produce a watery substance that may explain female "ejaculation". The tissue surrounding these glands, which includes the part of th More Tadalafil Current Events and Tadalafil News Articles |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||